問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間：2023-09-19

張俊欽
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張俊欽

List

42Cases

2025-07-01 - 2028-05-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease (ASCVD)

  • Test Drug

    預充填式注射劑

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2027-03-31

Phase III

Active
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

  • Condition/Disease

    ASCVD, CKD and systemic inflammation

  • Test Drug

    Ziltivekimab B 15 mg/ml / placebo

Participate Sites
12Sites

Recruiting9Sites

Terminated3Sites

2023-05-08 - 2027-07-02

Phase III

Active
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.

  • Condition/Disease

    heart failure

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting5Sites

2025-10-01 - 2030-06-30

Phase III

Active
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

  • Condition/Disease

    Type 2 diabetes mellitus, hypertension, and established cardiovascular disease

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
11Sites

Recruiting11Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and Hypertension

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
11Sites

Not yet recruiting5Sites

Recruiting6Sites

2024-07-30 - 2028-09-30

Phase III

EASi-HF – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

  • Condition/Disease

    heart failure

  • Test Drug

    BI 690517empagliflozin

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2022-06-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-03-01 - 2027-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2021-05-18 - 2023-12-31

Phase II

A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD9977及Dapagliflozin

Participate Sites
10Sites

Not yet recruiting5Sites

Recruiting5Sites

2022-01-19 - 2027-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting2Sites

Recruiting7Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB